Inventiva SA
PAR:IVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Inventiva SA
Cash from Operating Activities
Inventiva SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Cash from Operating Activities
-€162m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Operating Activities
-€52.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Operating Activities
-€26.2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-6%
|
|
|
Cellectis SA
PAR:ALCLS
|
Cash from Operating Activities
-$39.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash from Operating Activities
-$120.5m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-16%
|
|
|
Abivax SA
PAR:ABVX
|
Cash from Operating Activities
-€154.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-26%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Cash from Operating Activities?
Cash from Operating Activities
-162m
EUR
Based on the financial report for Dec 31, 2025, Inventiva SA's Cash from Operating Activities amounts to -162m EUR.
What is Inventiva SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-40%
Over the last year, the Cash from Operating Activities growth was -89%. The average annual Cash from Operating Activities growth rates for Inventiva SA have been -53% over the past three years , -40% over the past five years .
